Dosing underway in Nektar study of NKTR-255+cetuximab in head, neck, colorectal cancer

 

• The first patient has been dosed in Nektar Therapeutics' (NASDAQ:NKTR) Phase 1/2 trial of NKTR-255 in patients with relapsed or refractory (R/R) head and neck squamous cell carcinoma (HNSCC) or colorectal cancer (CRC) at the START Center for Cancer Care in San Antonio, TX.
• The study is evaluating NKTR-255 plus cetuximab in up to 80 patients.
• NKTR-255 is an investigational IL-15 receptor agonist designed to activate the IL-15 pathway and expand Natural Killer cells and promote the survival and expansion of memory CD8+ T cells without inducing suppressive regulatory T cells.
• Cetuximab is a monoclonal antibody against epidermal growth factor receptor and is approved for the treatment of advanced HNSCC and CRC.
• https://seekingalpha.com/news/3644434-dosing-underway-in-nektar-therapeutics-study-of-nktrminus-255-pluscetuximab-in-head-neck-and